Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103578 | 0.91 | MAP4K4 (0.44) | MAP4K4EGFRKDRDRD2DRD3 | |
| Formic Acid SCHEMBL30455236 | 0.90 | EGFR (0.35) | MAP4K4EGFRKDRDRD2DRD3 | |
| SCHEMBL9934294 | 0.77 | MAP4K4 (0.39) | MAP4K4DRD2DRD3DRD4PIK3CA | |
| SCHEMBL9934420 | 0.73 | MAP4K4 (0.44) | MAP4K4DRD2DRD3DRD4PIK3CA | |
| SCHEMBL21855867 | 0.73 | MAP4K4 (0.39) | MAP4K4DRD2DRD3DRD4PIK3CA | |
| SCHEMBL25472754 | 0.73 | MAP4K4 (0.39) | MAP4K4DRD2DRD3DRD4PIK3CA | |
| SCHEMBL2849280 | 0.73 | MAP4K4 (0.53) | MAP4K4EGFRDRD2DRD3DRD4 | |
| SCHEMBL30081468 | 0.73 | MAP4K4 (0.39) | MAP4K4EGFRKDRDRD2DRD3 | |
| SCHEMBL20265768 | 0.73 | MAP4K4 (0.39) | MAP4K4DRD2DRD3DRD4PIK3CA | |
| SCHEMBL8887892 | 0.73 | MAP4K4 (0.40) | MAP4K4EGFRKDRDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0467637-B1 | Pyrazolo(1,5-a)pyridine compounds, and production and use thereof | SENJU PHARMA CO (JP) | 1995-10-18 | — | — | EP | claimed |
| US-5202334-A | Pyrazolo[1,5-a]pyridine compounds, and production and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | claimed |
| EP-0467637-A1 | Pyrazolo(1,5-a)pyridine compounds, and production and use thereof | Senju Pharmaceutical Co., Ltd. (JP) | 1992-01-22 | — | — | EP | claimed |
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-112074522-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-112074523-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-112074521-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008113559-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | SCHWARZ PHARMA AG (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1972628-A1 | Indolizines and aza-analog derivatives thereof as CNS active compounds | SCHWARZ PHARMA AG (DE) | 2008-09-24 | — | — | EP | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-0467637-B1 | Pyrazolo(1,5-a)pyridine compounds, and production and use thereof | SENJU PHARMA CO (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5202334-A | Pyrazolo[1,5-a]pyridine compounds, and production and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0467637-A1 | Pyrazolo(1,5-a)pyridine compounds, and production and use thereof | Senju Pharmaceutical Co., Ltd. (JP) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | MAP4K4 4865/4885EGFR 1282/4885KDR 2098/4885 |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | PDE5A, PDE3A, PDE3B | MAP4K4 337/4885EGFR 4774/4885KDR 2005/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | MAP4K4 4186/4885EGFR 1987/4885KDR 3489/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | MAP4K4 3512/4885EGFR 1677/4885KDR 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.